Cargando…
VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
BACKGROUND: Combination of fluoropyrimidines and a platinum derivative are currently standards for systemic chemotherapy in advanced adenocarcinoma of the stomach and gastroesophageal junction (GEJ). Nevertheless, individual likelihood for response to these therapeutic regimes remains uncertain. Eve...
Autores principales: | Thomaidis, Thomas, Maderer, Annett, Al-Batran, Salah-Eddin, Kany, Janis, Pauligk, Claudia, Steinmetz, Kristina, Schad, Arno, Hofheinz, Ralf, Schmalenberg, Harald, Homann, Nils, Galle, Peter Robert, Moehler, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094395/ https://www.ncbi.nlm.nih.gov/pubmed/24981311 http://dx.doi.org/10.1186/1471-2407-14-476 |
Ejemplares similares
-
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Lordick, F, et al.
Publicado: (2010) -
Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Luber, Birgit, et al.
Publicado: (2011) -
Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
por: Lorenzen, S, et al.
Publicado: (2013) -
Burnout among German oncologists: a cross-sectional study in cooperation with the Arbeitsgemeinschaft Internistische Onkologie Quality of Life Working Group
por: Helaß, Madeleine, et al.
Publicado: (2022) -
Qualitätssicherung zur Therapie des muskelinvasiven und metastasierten Harnblasenkarzinoms in Deutschland: Eine Initiative der Arbeitsgemeinschaften Urologische Onkologie (AUO) und Internistische Onkologie (AIO) in der Deutschen Krebsgesellschaft (DKG)
por: Ohlmann, C. H., et al.
Publicado: (2022)